Economic evaluation of a JAK inhibitor compared to a monoclonal antibody for treatment of moderate-to-severe atopic dermatitis from a UK perspective-Reference-Cited by-同舟云学术

Economic evaluation of a JAK inhibitor compared to a monoclonal antibody for treatment of moderate-to-severe atopic dermatitis from a UK perspective

Published:2022-04-09 Issue:1 Volume:25 Page:491-502
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Heinz Katja C.¹,Willems Damon¹^ORCID,Hiligsmann Mickaël¹^ORCID

Affiliation:

1. Department of Health Services Research, Care and Public Health Research Institute (CAPHRI), Faculty of Health Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2022.2059220

Reference41 articles.

1. Adult eczema prevalence and associations with asthma and other health and demographic factors: A US population–based study

2. Epidemiology of atopic dermatitis in adults: Results from an international survey

3. Avail Dermatology. Top 5 Most Common Skin Conditions. 2018. [cited 2021 Jun 10]. Available from: https://availdermatology.com/common-skin-conditions/.

4. Atopic Dermatitis

5. Burden of skin pain in atopic dermatitis

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Budget impact and cost per responder analysis of upadacitinib for the treatment of moderate to severe atopic dermatitis from the perspective of the social security and the private sector in Argentina;Expert Review of Pharmacoeconomics & Outcomes Research;2024-08-30

2. Monoclonal Antibodies: Current Advancements and Future Potential for Atopic Dermatitis Therapy;Current Pharmaceutical Biotechnology;2024-06-25

3. Estimation of health utility values for alopecia areata;Quality of Life Research;2024-03-29

4. Analysis of the economic burden associated with comparing biological therapy to traditional conventional therapies for the treatment of moderate-to-severe atopic dermatitis.;2024-01-09

5. Methotrexate therapy for adult and paediatric moderate‐to‐severe atopic dermatitis: A PRISMA‐compliant meta‐analysis of data from daily practice;Australasian Journal of Dermatology;2023-11-08